GLP-1 Cardio Market Analysis, Size, Share & Growth Forecast 2026–2034

SELECT Trial 20 Percent MACE Reduction in 17,604 Non-Diabetic Obese Patients With Established CVD Has Created the FDA Cardiovascular Risk Reduction Indication That Extends Semaglutide Beyond Diabetes and Obesity to the Non-Diabetic High-Cardiovascular-Risk Patient.Novo Nordisk's SUSTAIN and PIONEER semaglutide CVOT trials established GLP-1 agonist cardiovascular safety and benefit in diabetic patients with or at high risk of cardiovascular disease, and the SELECT trial's extension to non-diabetic obese patients with prior MI or stroke validated the cardiovascular mechanism as independent of glucose lowering. The 20% MACE reduction in SELECT across 17,604 patients over an average of 3.3 years follow-up translates to approximately 4 events prevented per 100 patients treated, a clinically and economically meaningful benefit that positions semaglutide as a cardiovascular medicine rather than simply an obesity drug. The cardiovascular benefit of GLP-1 therapy is proposed to involve multiple mechanisms including plaque stabilisation through adipose tissue-derived inflammation reduction, direct cardiomyocyte protective effects during ischaemia, reduced systolic blood pressure, and triglyceride and inflammatory biomarker reduction.

FLOW Renal Outcome Trial 24 Percent Composite Renal Outcome Reduction in CKD With Type 2 Diabetes Has Established the GLP-1 Renal Protection Indication Extending Semaglutide Clinical Benefit to Kidney Disease Progression Prevention.Novo Nordisk's liraglutide demonstrated 13% MACE reduction in LEADER across 9,340 high-risk type 2 diabetes patients, and the consistency of benefit across SUSTAIN, LEADER, REWIND, and HARMONY established that the cardiovascular protection is a class effect of GLP-1 receptor agonism rather than an idiosyncratic property of specific molecules. The class effect interpretation is supported by the similar MACE reduction hazard ratios of 0.74-0.87 across approved GLP-1 agents with cardiovascular outcomes trials, with the variation explained by trial design differences in baseline risk and concomitant therapy rather than differential molecular pharmacology. The class effect recognition enabled regulatory extrapolation where orforglipron's MACE reduction demonstrated in its cardiovascular outcomes programme can be used to support a cardiovascular indication for other oral GLP-1 agents in the same class without repeated outcome trial requirements.

STEP-HFpEF Semaglutide KCCQ and 6-Minute Walk Improvement in Obese HFpEF Has Established the GLP-1 Agonist Benefit in Obesity-Related Preserved Ejection Fraction Heart Failure That Positions the Drug Class as the Treatment for the Obesity-Driven Cardiac Phenotype.Novo Nordisk's STEP-HFpEF demonstrated 7.8-point KCCQ score improvement and 6-minute walk improvement in obese HFpEF patients treated with semaglutide 2.4 mg versus placebo, providing the first pharmacotherapy for obese HFpEF patients where no other drug had demonstrated symptom improvement in controlled trials. The HFpEF mechanism for semaglutide is proposed to involve improvement in cardiac diastolic function through epicardial and pericardial fat reduction, reduced ventricular stiffness from weight-associated haemodynamic improvement, and direct anti-inflammatory effects on myocardial interstitial fibrosis. The STEP-HFpEF results position semaglutide for a dedicated HFpEF indication that would complement its existing cardiovascular prevention and obesity labels, creating a multi-indication cardiovascular platform that extends GLP-1 prescribing from endocrinology and obesity medicine into advanced heart failure management.

For related market intelligence, see the Diabetes Drug Market.